These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 29960957)
41. [Levodopa-carbidopa intestinal gel in the treatment of patients with Parkinson disease: results of a 12-month open study]. Skoromets AA; Odinak MM; Yakupov EZ; Litvinenko IV; Zalyalova ZA; Timofeeva AA; Kirtaev SY; Bogdanov RR; Agafina AS; Chatamra K; Robieson W; Benesh J; Latypova GR; Ershova MV; Illarioshkin SN Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(2):22-31. PubMed ID: 28374689 [TBL] [Abstract][Full Text] [Related]
42. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review. Wirdefeldt K; Odin P; Nyholm D CNS Drugs; 2016 May; 30(5):381-404. PubMed ID: 27138916 [TBL] [Abstract][Full Text] [Related]
43. The effect of levodopa-carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience. Băjenaru O; Ene A; Popescu BO; Szász JA; Sabău M; Mureşan DF; Perju-Dumbrava L; Popescu CD; Constantinescu A; Buraga I; Simu M J Neural Transm (Vienna); 2016 Apr; 123(4):407-14. PubMed ID: 26699635 [TBL] [Abstract][Full Text] [Related]
49. Duodopa infusion treatment: a point of view from the gastroenterologist. Negreanu L; Popescu BO; Babiuc RD; Ene A; Bajenaru OA; Smarandache GC J Gastrointestin Liver Dis; 2011 Sep; 20(3):325-7. PubMed ID: 21961105 [TBL] [Abstract][Full Text] [Related]
50. Impact of Disease Duration in Effectiveness of Treatment with Levodopa-Carbidopa Intestinal Gel and Factors Leading to Discontinuation. Regidor I; Santos-García D; Catalán MIJ; Puente V; Valldeoriola F; Grandas F; Mir P; Parra JC; Arbelo JM J Parkinsons Dis; 2019; 9(1):173-182. PubMed ID: 30562907 [TBL] [Abstract][Full Text] [Related]
51. A clinically silent, but severe, duodenal complication of duodopa infusion. Bianco G; Vuolo G; Ulivelli M; Bartalini S; Chieca R; Rossi A; Rossi S J Neurol Neurosurg Psychiatry; 2012 Jun; 83(6):668-70. PubMed ID: 22544946 [No Abstract] [Full Text] [Related]
52. Transcutaneous port for continuous duodenal levodopa/carbidopa administration in Parkinson's disease. Meppelink AM; Nyman R; van Laar T; Drent M; Prins T; Leenders KL Mov Disord; 2011 Feb; 26(2):331-4. PubMed ID: 20960486 [TBL] [Abstract][Full Text] [Related]
53. [Continuous treatment with levodopa of Parkinson disease]. Lundqvist C; Nystedt T; Reiertsen O; Grotli R; Beiske AG Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2638-40. PubMed ID: 16215609 [TBL] [Abstract][Full Text] [Related]
54. The impact of tube replacement timing during LCIG therapy on PEG-J associated adverse events: a retrospective multicenter observational study. Yamashita K; Yube Y; Yamazaki Y; Fukuchi T; Kato M; Koike T; Uehara T; Ikeda Y; Furune S; Murakami H; Kubota E; Fujioka S; Sato Y; Jin X; Suzuki T; Furukawa K; Tsuboi Y BMC Neurol; 2021 Jun; 21(1):242. PubMed ID: 34172002 [TBL] [Abstract][Full Text] [Related]
55. Clinical management of patients with advanced Parkinson's disease treated with continuous intestinal infusion of levodopa/carbidopa. Santos García D; Martínez Castrillo JC; Puente Périz V; Seoane Urgorri A; Fernández Díez S; Benita León V; Udaeta Baldivieso B; Campolongo Perillo A; Mariscal Pérez N Neurodegener Dis Manag; 2016 Jun; 6(3):187-202. PubMed ID: 27075968 [TBL] [Abstract][Full Text] [Related]
56. Cost-utility analysis of levodopa carbidopa intestinal gel (Duodopa) in the treatment of advanced Parkinson's disease in patients in Scotland and Wales. Kalabina S; Belsey J; Pivonka D; Mohamed B; Thomas C; Paterson B J Med Econ; 2019 Mar; 22(3):215-225. PubMed ID: 30484353 [TBL] [Abstract][Full Text] [Related]